In a pilot study performed in early-stage breast cancer patients, the short-term administration of rosiglitazone failed to reduce breast tumor proliferation, reduced insulin resistance, and increased serum adiponectin levels, which are considered breast cancer risk factors [45]. The gene discussed is ADIPOQ; the disease is breast carcinoma.